OR WAIT 15 SECS
June 2, 2015.
The rheumatoid arthritis (RA) therapeutics market in the Asia-Pacific (APAC) region will expand from $5.6 billion in 2014 to an estimated $7 billion by 2021, according to GBI Research.
The company states that of the four major APAC countries - Australia, China, India and Japan - the latter will retain the largest share, with its market value expanding from approximately $4.1 billion in 2014 to $4.7 billion by 2021.
GBI analyst Sumith Ladda said the entry of new therapies over the forecast period will stimulate market growth, with promising pipeline candidates including Eli Lilly and Incyte’s baricitinib, Johnson & Johnson and GlaxoSmithKline’s sirukumab, and Sanofi and Regeneron’s sarilumab.
“Generic first-line drugs, such as Methotrexate, and symptomatic drugs will remain the mainstay of treatment for mild-to-severe RA," said Ladda, but second-line therapies "will play a greater role in shaping the overall market by 2021". Given the crowded arena, emerging second-line drugs are likely to establish themselves gradually.